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Nelson ChaoGraft-versus-host disease (GVHD) has been classi-
cally divided into acute and chronic disease based upon
the time of onset with chronic GVHD (cGVHD) oc-
curring after day 100. However, this division at day
100 is artificial. There has been a shift toward defining
acuteGVHD (aGVHD) and cGVHDbased upon clin-
ical manifestations, rather than the arbitrary cutoff of
a particular date posttransplantation. A major step for-
ward was taken in 2005, when a National Institutes of
Health (NIH) consensus conference was held to
refine methods for research in cGVHD, including
proposedobjective responsemeasures andaprovisional
algorithm for calculating organ-specific and overall
response. For unclear cases, the NIH consensus diag-
nostic criteria for GVHD includes an overlap syn-
drome in which diagnostic or distinctive features of
cGVHD and aGVHD appear together. Patients with
cGVHD have skin involvement resembling lichen pla-
nus or the cutaneous manifestations of scleroderma,
dry oral mucosa with ulcerations and sclerosis of the
gastrointestinal tract, and a rising serum bilirubin con-
centration. The presenting symptoms are highly vari-
able and in some ways similar to those found in other
well-established autoimmune syndromes.
The variable presentation of cGVHD makes
clinical therapeutic studies difficult, because compari-
son of responses may be different depending on the se-
verity of involvement as well as the involved target
organ. The difficulty is further compounded by
whether one is a ‘‘lumper’’ or ‘‘splitter,’’ that is,
whether all cGVHDs are single disease processes
with variable presentations, or whether they are possi-
bly different diseases—as different, for example, as
scleroderma is from rheumatoid arthritis. The concern
here is that newer medications may work for one and
not the other, increasing the risk that a good drug
does not provide a positive signal due to the wrong pa-
tients being studied. So why has it been so very difficult
to move the area of cGVHD therapeutics forward?
The authors of ‘‘Poor Agreement betweenClinician
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ld D. and Elizabeth G. Cooke Professor Chief, Division
ematologic Malignancies and Cellular Therapy/BMT,[1] provide important insight into this conundrum.
Inamoto et al. [2] used weighted kappa statistics to eval-
uate the level of agreement between clinician response
ratings and calculated response categories in 290 pa-
tients with cGVHD who had paired enrollment and
follow-up visits. Based on a set of objective measures,
37% of the patients had an overall complete or partial
response, whereas clinicians reported an overall com-
plete or partial response rate of 71% (slight to fair
agreement, weighted kappa 0.20). Agreement rates
between calculated organ-specific responses and
clinician-reported changes in skin, mouth, and eyes
were fair to moderate (weighted kappa 0.28-0.54).
They conclude that for both overall and organ-
specific comparisons, clinician response ratings did
not agree well with calculated response categories.
Why the lack of agreement? The easiest answer is
that there is no clear way to measure the extent of dis-
ease or the response. Remember that cGVHD is a clin-
ical diagnosis. We can tell when it is black or white,
but we are not very good at distinguishing shades of
gray. We do not have a biomarker for cGVHD, and
so we rely on our clinical acumen to make the determi-
nation. Clinical acumen, by definition, changes with
practice and experience; hopefully, the more experi-
ence (probably to a certain point), the better intraob-
server correlation. We are in the business of the
practice of medicine and not the assembly line of med-
icine—just checking boxes (one can always have
hope)—but it is not so simple. We as treating physi-
cians want our patients to improve and perhaps this
also clouds our judgment, leading us to score improve-
ments more than we should. On the other hand, it is
important to realize that there may be limits as to
what is really important. One specific area that was
missing in this article was the grading on performance
status and quality of life (being prepared for a separate
publication). I would argue that it is not possible to
complete the assessment of cGVHD without the in-
clusion of a patient’s performance status and quality
of life. I can easily envision a physician (me in this
case) declaring a complete remission in a patient2400 Pratt St, Suite 9100, Box 3961, Durham, NC 27710.
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mance status, complete resolution from extensive
cGVHD, and off all immunosuppressive drugs. Or,
for example, in a 65-year-old patient who has indeed
achieved a complete remission, I may be reluctant to
wean that patient off the last 5 mg of prednisone. In
many ways, perhaps we need a very good partial re-
sponse level for cGVHD, similar to what has been
suggested for aGHVD [3].
It would also have been helpful to know if the
differences in response were clouded by whether a pa-
tient was on a particular study drug compared with
those on prednisone alone. One obvious concern is
physician bias in calling responses for those patients
on an investigational drug [4]. The authors are to be
commended for calling our attention to this, as conclu-
sions from prior literature reporting high overall re-
sponse rates based on clinician judgment would not
be supported if the provisional algorithm had been ap-
plied to calculate response. These data again highlight
the importance of research rigor in cGVHD studies.
There are other factors that make cGVHD difficult
to study, not the least of which is that many of the pa-
tients are frequently far away from the medical center,
making both evaluation and certain therapies (ie,
photopheresis) difficult.
This analysis highlights the need to prospectively
define an overall response measure that incorporates
both patient-reported and objective measures, and ac-
curately reflects the outcome in patients. This is espe-
cially true when there is a mixed response where one
organ or site improves, while another shows new in-
volvement. What these data demonstrate is that we
very much need the validation of the NIH consensus
criteria, the studies of which are ongoing. Our field
would benefit considerably from something similar
to the Rodnan scores for systemic sclerosis. I would
argue that we are in a similar situation as the rheuma-From the Ohio State University Comprehensive Cancer Center,
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Despite some concerns regarding this instrument, it
has been pivotal in allowing for a uniform language,
measuring the disease, and facilitating progress in the
choice of therapies.
In summary, we are reminded of the curmudgeon
H.L. Mencken who stated, ‘‘For every complex prob-
lem, there is a solution that is simple, neat, and
wrong.’’ The authors of this article have provided
a very important framework for clinical trials going
forward.We must measure with greater rigor and pre-
cision if we want to help our patients.We as a commu-
nity must also show our commitment to our patients
by participating in large, well-designed studies such
as those led by the Clinical Trials Network. We need
clear definitions that can be understood by all, studies
with sufficient patients that allow for robust statistics,
and a measure of thought regarding the biology of this
disease process.ACKNOWLEDGMENTS
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